| scholarly article | Q13442814 |
| P2093 | author name string | Yang Li | |
| Jun Zhang | |||
| P2860 | cites work | Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys | Q46844955 |
| Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. | Q47931952 | ||
| A novel approach to improve the function of FGF21. | Q48506046 | ||
| Association between serum fibroblast growth factor 21 and diabetic nephropathy. | Q51364488 | ||
| A nontumorigenic variant of FGF19 treats cholestatic liver diseases. | Q53233233 | ||
| Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue. | Q53514538 | ||
| Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. | Q54468633 | ||
| Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques | Q57500042 | ||
| Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes | Q82108485 | ||
| [Optimization and characterization of a novel FGF21 mutant] | Q85001479 | ||
| Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction | Q87417998 | ||
| Identification of a novel FGF, FGF-21, preferentially expressed in the liver | Q22254289 | ||
| betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c | Q24306279 | ||
| Different roles of N- and C- termini in the functional activity of FGF21 | Q24312210 | ||
| C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors | Q24317949 | ||
| Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 | Q24318639 | ||
| FGF21 N- and C-termini play different roles in receptor interaction and activation | Q24322074 | ||
| FGF-21 as a novel metabolic regulator | Q24523933 | ||
| Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State | Q24625976 | ||
| Endocrine fibroblast growth factors 15/19 and 21: from feast to famine | Q24629260 | ||
| Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo | Q24632545 | ||
| Fibroblast growth factor 21: from pharmacology to physiology | Q24658126 | ||
| BetaKlotho is required for metabolic activity of fibroblast growth factor 21 | Q24681531 | ||
| Inventing new medicines: The FGF21 story | Q26823319 | ||
| FGF21 promotes metabolic homeostasis via white adipose and leptin in mice | Q27335466 | ||
| Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer | Q28244332 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| Fibroblast growth factor receptors, developmental corruption and malignant disease | Q28295085 | ||
| Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese | Q28477784 | ||
| A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol | Q28478454 | ||
| Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes | Q28485340 | ||
| Regulation of fibroblast growth factor-23 signaling by klotho | Q28587100 | ||
| Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models | Q28729944 | ||
| Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism | Q28730955 | ||
| FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways | Q28741802 | ||
| Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states | Q29615208 | ||
| Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21 | Q29615209 | ||
| Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. | Q30355232 | ||
| Serum FGF21 levels are associated with brown adipose tissue activity in humans. | Q30374773 | ||
| FGF21 contributes to neuroendocrine control of female reproduction | Q30414627 | ||
| FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation | Q33648263 | ||
| Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile | Q33785827 | ||
| Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis | Q34019712 | ||
| Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). | Q34069794 | ||
| The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. | Q34306190 | ||
| Monoclonal antibody targeting of fibroblast growth factor receptor 1c ameliorates obesity and glucose intolerance via central mechanisms | Q34575896 | ||
| The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. | Q34577053 | ||
| Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia | Q34603360 | ||
| FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein | Q34695496 | ||
| Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. | Q34778879 | ||
| Thermogenic activation induces FGF21 expression and release in brown adipose tissue. | Q34787051 | ||
| LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys | Q34792753 | ||
| Fibroblast growth factor 21 corrects obesity in mice | Q34805555 | ||
| Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease | Q35020888 | ||
| Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy | Q35210714 | ||
| FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis | Q35755169 | ||
| Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes | Q35762326 | ||
| Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. | Q35779219 | ||
| Evolution of the Fgf and Fgfr gene families | Q35913683 | ||
| Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands | Q35943927 | ||
| Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex | Q35947503 | ||
| A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis | Q35981284 | ||
| Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets | Q36061647 | ||
| Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate | Q36122162 | ||
| Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis | Q36196772 | ||
| Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor | Q36217292 | ||
| βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism | Q36248720 | ||
| Mild cold exposure modulates fibroblast growth factor 21 (FGF21) diurnal rhythm in humans: relationship between FGF21 levels, lipolysis, and cold-induced thermogenesis. | Q36508902 | ||
| An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice | Q36886578 | ||
| Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. | Q36953853 | ||
| Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease | Q37153759 | ||
| FGF21 regulates metabolism and circadian behavior by acting on the nervous system | Q37161082 | ||
| High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling | Q37251086 | ||
| Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity | Q37328872 | ||
| Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease | Q37781747 | ||
| Hormone-like fibroblast growth factors and metabolic regulation | Q37866879 | ||
| Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities | Q37991264 | ||
| Circulating fibroblast growth factors as metabolic regulators--a critical appraisal | Q38065349 | ||
| FGF21-based pharmacotherapy--potential utility for metabolic disorders | Q38202720 | ||
| The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target | Q38235454 | ||
| PPARalpha is a key regulator of hepatic FGF21. | Q38300403 | ||
| Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody | Q38315161 | ||
| A unique FGF23 with the ability to activate FGFR signaling through both αKlotho and βKlotho | Q38327362 | ||
| Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice | Q38350544 | ||
| Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects | Q38351110 | ||
| Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. | Q39427414 | ||
| Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. | Q39581682 | ||
| FGF21 reloaded: challenges of a rapidly growing field | Q39798117 | ||
| FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents | Q40667176 | ||
| Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. | Q40895648 | ||
| Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1. | Q40958865 | ||
| Fibroblast growth factor 21 protects the heart from oxidative stress. | Q41652869 | ||
| Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. | Q41760918 | ||
| The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue | Q41912342 | ||
| FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity | Q42813458 | ||
| FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho | Q42819634 | ||
| Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride | Q42950501 | ||
| Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. | Q42972684 | ||
| Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice | Q43224118 | ||
| Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. | Q43287114 | ||
| Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice | Q44479758 | ||
| Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice | Q44504595 | ||
| The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes | Q45834496 | ||
| Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects | Q46076306 | ||
| Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities | Q46122625 | ||
| Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation | Q46323104 | ||
| Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. | Q46527697 | ||
| Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice | Q46640076 | ||
| Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans | Q46770146 | ||
| P304 | page(s) | 168 | |
| P577 | publication date | 2015-11-05 | |
| P1433 | published in | Frontiers in Endocrinology | Q27723680 |
| P1476 | title | Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders | |
| P478 | volume | 6 |
| Q52372561 | A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity. |
| Q90428920 | A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling |
| Q55381461 | Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women. |
| Q59449558 | Cellular Stresses and Stress Responses in the Pathogenesis of Insulin Resistance |
| Q90667906 | Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice |
| Q47919673 | FGF21 Attenuates High-Fat Diet-Induced Cognitive Impairment via Metabolic Regulation and Anti-inflammation of Obese Mice |
| Q57688659 | FGF21 gene therapy as treatment for obesity and insulin resistance |
| Q39017842 | Fibroblast growth factor 21 night watch: advances and uncertainties in the field |
| Q26747742 | Finding Ponce de Leon's Pill: Challenges in Screening for Anti-Aging Molecules |
| Q60044667 | Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease |
| Q39062369 | Macronutrient Intake-Associated FGF21 Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial |
| Q90300458 | Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study |
| Q90324838 | Recombinant FGF21 Protects Against Blood-Brain Barrier Leakage Through Nrf2 Upregulation in Type 2 Diabetes Mice |
| Q92049636 | The Level of FGF 21 as a New Risk Factor for the Occurrence of Cardiometabolic Disorders amongst the Psoriatic Patients |
Search more.